Control of the immune response by pro-angiogenic factors - PubMed (original) (raw)
Review
Control of the immune response by pro-angiogenic factors
Thibault Voron et al. Front Oncol. 2014.
Abstract
The progressive conversion of normal cells into cancer cells is characterized by the acquisition of eight hallmarks. Among these criteria, the capability of the cancer cell to avoid the immune destruction has been noted. Thus, tumors develop mechanisms to become invisible to the immune system, such as the induction of immunosuppressive cells, which are able to inhibit the development of an efficient immune response. Molecules produced in the tumor microenvironment are involved in the occurrence of an immunosuppressive microenvironment. Recently, it has been shown that vascular endothelial growth factor A (VEGF-A) exhibits immunosuppressive properties in addition to its pro-angiogenic activities. VEGF-A can induce the accumulation of immature dendritic cells, myeloid-derived suppressor cells, regulatory T cells, and inhibit the migration of T lymphocytes to the tumor. Other pro-angiogenic factors such as placental growth factor (PlGF) could also participate in tumor-induced immunosuppression, but only few works have been performed on this point. Here, we review the impact of pro-angiogenic factors (especially VEGF-A) on immune cells. Anti-angiogenic molecules, which target VEGF-A/VEGFR axis, have been developed in the last decades and are commonly used to treat cancer patients. These drugs have anti-angiogenic properties but can also counteract the tumor-induced immunosuppression. Based on these immunomodulatory properties, anti-angiogenic molecules could be efficiently associated with immunotherapeutic strategies in preclinical models. These combinations are currently under investigation in cancer patients.
Keywords: MDSC; PlGF; VEGF-A; immunosuppression; immunotherapy; pro-angiogenic factors; regulatory T cells; tumor.
Figures
Figure 1
VEGFR signaling pathways.
Figure 2
Pro-angiogenic factors induce the development of an immunosuppressive state in tumors. VEGF-A induces the accumulation of MDSC, immature DC, Treg, and tumor-associated macrophages (TAM). MDSC and Treg are able to control activation of T cells and NK cells.
Similar articles
- The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.
Tamura R, Tanaka T, Akasaki Y, Murayama Y, Yoshida K, Sasaki H. Tamura R, et al. Med Oncol. 2019 Nov 11;37(1):2. doi: 10.1007/s12032-019-1329-2. Med Oncol. 2019. PMID: 31713115 Review. - The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment.
Hu C, Jiang X. Hu C, et al. Biomed Pharmacother. 2017 Apr;88:134-137. doi: 10.1016/j.biopha.2017.01.051. Epub 2017 Jan 16. Biomed Pharmacother. 2017. PMID: 28103506 Review. - Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP, Zhu AX, Wang Y. Hack SP, et al. Front Immunol. 2020 Nov 5;11:598877. doi: 10.3389/fimmu.2020.598877. eCollection 2020. Front Immunol. 2020. PMID: 33250900 Free PMC article. Review. - Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
Bourhis M, Palle J, Galy-Fauroux I, Terme M. Bourhis M, et al. Front Immunol. 2021 Mar 29;12:616837. doi: 10.3389/fimmu.2021.616837. eCollection 2021. Front Immunol. 2021. PMID: 33854498 Free PMC article. Review. - Modulation of immunity by antiangiogenic molecules in cancer.
Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Terme M, et al. Clin Dev Immunol. 2012;2012:492920. doi: 10.1155/2012/492920. Epub 2012 Dec 24. Clin Dev Immunol. 2012. PMID: 23320019 Free PMC article. Review.
Cited by
- Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications.
Zheng X, Sun R, Wei T. Zheng X, et al. Front Immunol. 2024 Sep 3;15:1438235. doi: 10.3389/fimmu.2024.1438235. eCollection 2024. Front Immunol. 2024. PMID: 39290709 Free PMC article. Review. - Enhanced efficacy of combined VEGFR peptide-drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma.
Liu J, Bai Y, Liu X, Zhou B, Sun P, Wang Y, Ju S, Zhou C, Wang C, Yao W, Yang H, Jiang X, Yang L, Wang D, Zheng C. Liu J, et al. Sci Rep. 2024 Sep 17;14(1):21728. doi: 10.1038/s41598-024-72907-w. Sci Rep. 2024. PMID: 39289512 Free PMC article. - Metastatic adult Wilms' tumor managed by chemotherapy, immunotherapy and target therapy: a case report.
Zhao Q, Xiong Q, Song Q. Zhao Q, et al. Future Sci OA. 2024 May 16;10(1):FSO915. doi: 10.2144/fsoa-2023-0156. eCollection 2024. Future Sci OA. 2024. PMID: 38817367 Free PMC article. - A Molecular Perspective on HIF-1α and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update.
Magar AG, Morya VK, Kwak MK, Oh JU, Noh KC. Magar AG, et al. Int J Mol Sci. 2024 Mar 14;25(6):3313. doi: 10.3390/ijms25063313. Int J Mol Sci. 2024. PMID: 38542288 Free PMC article. Review. - Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study.
Domański P, Piętak M, Kruczyk B, Jarosińska J, Mydlak A, Demkow T, Darewicz M, Sikora-Kupis B, Dumnicka P, Kamzol W, Kucharz J. Domański P, et al. Biomedicines. 2024 Feb 9;12(2):413. doi: 10.3390/biomedicines12020413. Biomedicines. 2024. PMID: 38398014 Free PMC article.
References
- Thomas L. Discussion on Cellular and Humoral Aspects of the Hypersensitive States. New York: Hoeber; (1959). p. 529–32
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources